Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitors

This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

The company said the oral drug could rival the efficacy of injectable antibodies for psoriasis, and also have a better safety profile than other oral agents such as the JAK inhibitors.

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, CYT387, in clinical development and complementary to Gilead's ... YM Bioscience / Gilead. Company acquisition. JAK kinase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics